Oxana V. Makarova-Rusher

Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

S. Steinberg, P. Choyke, B. Wood, 2017, Clinical Cancer Research.

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

S. Steinberg, M. Raffeld, E. Levy, 2016, International journal of cancer.

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

A. LaCasce, M. Dwyer, Deborah A. Freedman-Cass, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

The yin and yang of evasion and immune activation in HCC.

T. Greten, A. Duffy, J. Medina-Echeverz, 2015, Journal of hepatology.

Population attributable fractions of risk factors for hepatocellular carcinoma in the United States

B. Graubard, S. Altekruse, K. McGlynn, 2016, Cancer.

Pancreatic Squamous Cell Carcinoma: A Population-Based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes

T. Greten, A. Duffy, S. Ulahannan, 2016, Pancreas.

Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.

S. Steinberg, T. Greten, M. Kurtoğlu, 2015, Hepatic oncology.

The case for immune‐based approaches in biliary tract carcinoma

T. Greten, A. Duffy, O. Makarova-Rusher, 2016, Hepatology.

A pilot study of AMP-224--a PD-1 inhibitor--in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.

B. Wood, T. Greten, D. Citrin, 2015 .